Company: TELO
Filing Date: 2025-08-07
Form Type: 8-K
Source: 0001641172-25-022506
Chunk: 0

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-08-07
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item
8.01 Other Events

Telomir
Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Inhibits Key Epigenetic Enzymes Driving Tumor Growth, Autoimmune Disease, Neurodegeneration,
and Metabolic Dysfunction

New
data from Eurofins Discovery show that Telomir-1 blocks enzymes that drive disease by turning off critical genes - highlighting its
potential to treat cancer, autoimmune conditions, neurodegeneration, and metabolic disorders through epigenetic modulation.

On
August 7, 2025, Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a preclinical-stage biotechnology company developing therapies that target
the underlying mechanisms of aging and age-related diseases, today announced new in vitro data supporting the mechanism of action of
its lead drug candidate, Telomir-1.

In
a preclinical study conducted in collaboration with Eurofins Discovery, Telomir-1 was shown to inhibit three key histone demethylase
enzymes - JMJD3, FBXL10, and FBXL11 - that regulate gene expression through epigenetic mechanisms. These enzymes function by
removing methyl groups from histones, effectively switching genes on or off. When overactive, they silence tumor suppressor genes and
activate pro-inflammatory or metabolic genes that contribute to disease.

Overactivation
of these enzymes can result from genetic amplification, chronic inflammation, and stress signals from the tumor microenvironment. These
factors can trigger persistent gene silencing or inappropriate activation of disease-promoting pathways, reinforcing their role in cancer,
immune disorders, and metabolic dysfunction.

Specifically:

  JMJD3 is associated with inflammation, metastasis, and immune signaling dysregulation. It is overexpressed  
  FBXL10 is known to drive aggressive cancers and promote resistance to therapy by maintaining cancer         
  FBXL11 contributes to tumor proliferation and immune evasion and has been linked to both metabolic          

By
inhibiting all three enzymes, Telomir-1 may help restore normal gene expression patterns in diseases characterized by epigenetic silencing,
making it a promising candidate across multiple high-burden indications.

Telomir-1’s
inhibition of these enzymes represents a potential breakthrough in the company’s effort to target upstream regulators of disease-related
gene silencing. The findings build upon previously disclosed results showing Telomir-1’s ability to reverse epigenetic silencing
of tumor suppressor genes such as STAT1 and TMS